|本期目录/Table of Contents|

[1]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566-570.
点击复制

膀胱癌外周血生物标志物研究进展(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24
期数:
2018年06期
页码:
566-570
栏目:
综 述
出版日期:
2018-11-20

文章信息/Info

Title:
-
作者:
刘 莉 康家旗 综 述刘晓强 审 校
(天津医科大学第二医院泌尿外科,天津市泌尿外科研究所,天津 300211)
Author(s):
-
关键词:
膀胱癌中性粒细胞淋巴细胞C反应蛋白白蛋白预后
Keywords:
-
分类号:
R737.14
DOI:
-
文献标志码:
A
摘要:
近年来,关于外周血生物标志物如外周血细胞计数、白蛋白、C反应蛋白等在各系统肿瘤治疗、预后方面的应用受到了广泛关注,其检测方法简单易行。膀胱癌是泌尿系统最常见的恶性肿瘤,容易复发和进展,临床诊治比较棘手。本文就外周血生物标志物在膀胱癌中应用的研究进展作一综述。
Abstract:
-

参考文献/References:


[1] Ferlay J. Soerjomataram I, Dikshit R, et al. GLOBOCAN 2012 v.1.0, estimated cancer incidence, mortality and prevalence worldwide in 2012[J]. International Agency for Research on Cancer, Lyon, France (2013)
[2] Burger M, Catto J W, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer[J]. Eur Urol, 2012,63(2):234
[3] van Rhijn B W, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy[J]. Eur Urol, 2009,56(3):430
[4] 那彦群,叶章群,孙颖浩,等. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社,2014: 435
[5] Zehnder P, Studer U E, Skinner E C, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades[J]. BJU Int, 2013,112(2):E51
[6] Stein J P, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients[J]. J Clin Oncol, 2001,19(3):666
[7] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow[J]. Lancet, 2001,357(9255):539
[8] Maletzki C, Emmrich J. Inflammation and immunity in the tumor environment[J]. Dig Dis, 2010,28(4-5):574
[9] Azab B, Bhatt V R, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients[J]. Ann Surg Oncol, 2011,19(1):217
[10] Ishizuka M, Nagata H, Takagi K, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer[J]. Br J Cancer, 2013, 109(2):401
[11] Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer[J]. Oncology, 2007,73(3/4):215
[12] Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thromoocytosis in patients with gastric cancer[J]. Ann Surg Oncol, 2002,9(3): 287
[13] Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer[J]. Cancer Immun, 2007, 7:4.
[14] Xue T C, Zhang L, Xie X Y, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis[J]. PLoS One, 2014,9(5):e96072
[15] D'Andrea D, Moschini M, Gust K, et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer[J]. Clin Genitourin Cancer, 2017,15(5):e755
[16] Mano R, Baniel J, Shoshany O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer[J]. Urol Oncol, 2014,33(2): 67.e1
[17] Kang M, Jeong C W, Kwak C, et al. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor[J]. Oncotarget, 2017,8(8):12891
[18] Ogihara K, Kikuchi E, Yuge K, et al. The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking[J]. Ann Surg Oncol, 2016,23(Suppl 5):1039
[19] 秦川, 杜智勇, 申忠华, 等. 术前外周血中性粒细胞与淋巴细胞比值评估高级别 T1期膀胱癌预后的临床价值[J]. 中华泌尿外科杂志, 2016,37(9):685
[20] Viers B R, Boorjian S A, Frank I, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy[J]. Eur Urol, 2014,66(6):1157
[21] Morizawa Y, Miyake M, Shimada K, et al. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy[J]. Urol Oncol, 2016,34(6): 257.e11
[22] Kawahara T, Furuya K, Nakamura M, et al. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy[J]. BMC Cancer, 2016,16:185.
[23] Kang M, Balpukov U J, Jeong C W, et al. Can the Preoperative Neutrophil-to-Lymphocyte Ratio Significantly Predict the Conditional Survival Probability in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy[J]. Clin Genitourin Cancer, 2017, 15(3):e411
[24] Grossman H B, Natale R B, Tangen C M, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer[J]. N Engl J Med, 2003,349(9):859
[25] van Kessel K E, de Haan L M, Fransen V D PE, et al. Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer[J]. Bladder Cancer, 2016,2(3):351
[26] Buisan O, Orsola A, Areal J, et al. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer[J]. Clin Genitourin Cancer, 2017, 15(1):145
[27] Buisan O, Orsola A, Oliveira M, et al. Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy[J]. Clin Genitourin Cancer, 2017,15(4):e697
[28] Leibowitz-Amit R, Israel A, Gal M, et al. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer[J]. Clin Oncol (R Coll Radiol), 2016,28(12):790
[29] Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment[J]. Cancers (Basel), 2014,6(3):1670
[30] Tranum B L, Haut A. Thrombocytosis: platelet kinetics in neoplasia[J]. J Lab Clin Med, 1974,84(5):615
[31] Ho-Tin-Noe B, Goerge T, Wagner D D. Platelets: guardians of tumor vasculature[J]. Cancer Res, 2009,69(14):5623
[32] Nishijima T F, Muss H B, Shachar S S, et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis[J]. Cancer Treat Rev, 2015,41(10):971
[33] Kwon H C, Kim S H, Oh S Y, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer[J]. Biomarkers, 2012, 17(3):216
[34] Temraz S, Mukherji D, Farhat Z A, et al. Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis[J]. BMC Urol, 2014,14:76
[35] Zhang G M, Zhu Y, Luo L, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy[J]. Tumour Biol, 2015,36(11):8537
[36] Yoshida T, Kinoshita H, Yoshida K, et al. A novel risk stratification model, involving preoperative lymphocyte-monocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy[J]. Jpn J Clin Oncol, 2015,45(12):1162
[37] D'Andrea D, Moschini M, Gust K M, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy[J]. J Surg Oncol, 2017,115(4):455
[38] 李健, 叶定伟, 姚旭东, 等. 术前血小板/淋巴细胞比值判断上尿路尿路上皮癌临床分期及预后的价值[J]. 中国癌症杂志, 2013, 23(6):457
[39] 刘霄, 唐菁, 李笃军. C-反应蛋白在肿瘤发生发展中的作用[J]. 生命的化学, 2011,31(6):868
[40] Tomimaru Y, Yano M, Takachi K, et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer[J]. J Am Coll Surg, 2005,202(1):139
[41] Palumbo J S, Talmage K E, Massari J V, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells[J]. Blood, 2004,105(1):178
[42] Shrotriya S, Walsh D, Bennani-Baiti N, et al. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review[J]. PLoS One, 2015,10(12):e143080.
[43] Huang J, Baum Y, Alemozaffar M, et al. C-reactive protein in urologic cancers[J]. Mol Aspects Med, 2015,45:28
[44] Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes[J]. Int J Urol, 2012,20(2):161
[45] Gakis G, Todenhofer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score[J]. BJU Int, 2011,108(11):1800
[46] Yoshida S, Saito K, Koga F, et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy[J]. BJU Int, 2008,101(8):978
[47] Eggers H, Seidel C, Schrader A J, et al. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder[J]. Med Oncol, 2013,30(4):705.
[48] Ma C, Lu B, Diao C, et al. Preoperative neutrophil-lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer[J]. Onco Targets Ther, 2016,9:4917
[49] Karl A, Staehler M, Bauer R, et al. Malnutrition and clinical outcome in urological patients[J]. Eur J Med Res, 2011,16(10):469
[50] Gregg J R, Cookson M S, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer[J]. J Urol, 2011,185(1):90
[51] Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study[J]. Arch Surg, 1999,134(1):36
[52] Djaladat H, Bruins H M, Miranda G, et al. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer[J]. BJU Int, 2013,113(6):887
[53] Lambert J W, Ingham M, Gibbs B B, et al. Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer[J]. Urology, 2013,81(3):587
[54] Chan E S, Yip S K, Hou S M, et al. Age, tumour stage, and preoperative serum albumin level are independent predictors of mortality after radical cystectomy for treatment of bladder cancer in Hong Kong Chinese[J]. Hong Kong Med J, 2013,19(5):400
[55] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation[J]. N Engl J Med, 1999,340(6):448
[56] Liu J, Dai Y, Zhou F, et al. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy[J]. Urol Oncol, 2016,34(11):481.e1

相似文献/References:

[1]呼沛然,李萌璐,杨 欢,等.体外实验中缺氧对中性粒细胞凋亡的影响[J].天津医科大学学报,2014,20(06):0.
 HU Pei-ran,LI Meng-lu,YANG Huan,et al. Effects of hypoxia on apoptosis of neutrophils in vitro [J].Journal of Tianjin Medical University,2014,20(06):0.
[2]呼沛然,李萌璐,杨 欢,等.体外实验中缺氧对中性粒细胞凋亡的影响[J].天津医科大学学报,2014,20(06):426.
 HU Pei-ran,LI Meng-lu,YANG Huan,et al. Effects of hypoxia on apoptosis of neutrophils in vitro [J].Journal of Tianjin Medical University,2014,20(06):426.
[3]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
 CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer(≤pT2N0M0)[J].Journal of Tianjin Medical University,2017,23(06):357.
[4]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
 MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(06):25.
[5]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
 LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(06):51.
[6]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
 FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(06):373.

备注/Memo

备注/Memo:
基金项目 天津市自然科学基金重点项目(16JCZDJC34600)
作者简介 刘莉(1981-),女,主管技师,硕士,研究方向:泌尿外科临床与基础研究;通信作者:刘晓强,E-mail:xiaoqiangliu1@163.com。
更新日期/Last Update: 2018-11-30